Background: Medication prior authorization (PA) is a commonly occurring requirement, particularly for medications used for rare conditions. Based on standard definitions, cancer and many blood disorders affecting children are rare. The study aims were to describe the relative frequency of PA requests and their association with payers and medications in order to identify opportunities to improve system efficiency.
INTRODUCTION
The prior authorization (PA) process is one method utilized by the payer system for regulation and cost containment. Medication PA policies were initially shown to reduce medication expenditures in the primary care setting for patients with hypercholesterolemia and hypertension. [1] [2] [3] While these studies demonstrated effectiveness at cost reduction, the clinical consequences of policy-induced drug switching were never analyzed. In a more recent large analysis of type 2 diabetes mellitus medications, PA did not lead to an overall cost Abbreviations: GDP, gross domestic product; PA, prior authorization; PHO, pediatric hematology and oncology savings. 4 Moreover, a subset of diabetic patients needing medication PA never filled their prescriptions, which led to an overall downstream increase in payer-paid costs. For antibiotic stewardship, the PA process showed benefit to patients by reducing broad-spectrum antibiotic usage. 5, 6 In the field of psychiatry, PA requirements were associated with an increase in mental illness in the criminal justice system. 7 Independently of direct patient-specific financial and clinical outcomes, the PA process adds a burden and expense to the health-care system as a whole. The cost estimate associated with resource utilization for claims processing is between $1 and $31 billion U.S. dollars. [8] [9] [10] Triggers for medication PA typically include high medication cost, frequent off-label use, high toxicity, and potentially harmful drug interactions, all common in pediatric hematology and oncology (PHO). [11] [12] [13] [14] Therefore, it is reasonable to suspect that the PA process is commonly encountered in this subspecialty. No published information exists regarding the relative frequency of PAs and consequent impact on overall costs, burden of care, and clinical outcomes in PHO. The primary purpose of this analysis was to determine the relative frequency of medication PA requests in a pediatric hematology oncology practice, the clinic staff time required to manage these requests, and the outcome of the PA (medication approval). Secondarily, we examined associations between PA request frequency and the relationship with medication categories and payer policies in order to identify potentially targetable approaches to enhance cancer care delivery efficiency. 
METHODS

Data
RESULTS
The study period included 150 clinic days and 5,583 patient visits. A total of 142 medication PA requests were received yielding a period prevalence rate equal to 2.5% of patient visits. Medications subject to PA requests represented a broad range of PHO practice (Fig. 1) . The largest proportion of PA requests (32%) was generated by prescriptions for immune system support. In this category, most PA requests were generated by intravenous immunoglobulin followed by filgrastim. Table 1 To elucidate the frequency of PA requests across different payers, we identified payers with each occurrence. Our data show great variability in payer policy. Almost half of all medication PA requests were generated by two payers, while others generated only a single request.
In order to determine whether or not this difference simply represented the proportion that these insurance companies represented in our payer mix, a comparison chart was generated with representation of the payer's prevalence in our mix and the percentage of PA requests (Fig. 3) . There appeared to be no relationship between the payer's prominence in our patient mix and the number of medication PA requests generated by the payer.
DISCUSSION
The "business as usual" approach to U.S. health-care expenditures (HCE) has been deemed economically disastrous. Experts predict that without change, HCE could reach or exceed 20% of the total U.S. gross domestic product (GDP) by the year 2020. 15, 16 The latest available data (2014) indicate that total U.S. HCE is roughly $3 trillion dollars, 
